ライフサイエンスコーパス: high-density lipoprotein

1 , high levels of triglycerides and decreased high-density lipoprotein).

2 the anti-atherogenic functions attributed to high density lipoprotein.

3 poprotein A-I (ApoA-I), a major component of high-density lipoprotein.

4 in duplicate for glucose, triglyceride, and high-density lipoprotein.

5 result of compensatory increases in ApoE on high-density lipoprotein.

6 nd APOE, respectively) and the generation of high density lipoproteins.

7 form lipid-protein particles reminiscent of high-density lipoproteins.

8 ome to control body mass, triglycerides, and high-density lipoproteins.

9 nd low-density lipoproteins whereas increase high-density lipoproteins.

10 teolysis and misfolding by binding to plasma high-density lipoproteins.

11 n, very-low-density lipoprotein (VLDL), LDL, high-density lipoprotein].

12 cholesterol efflux to apolipoprotein A-I and high-density lipoprotein-3 were qualitatively and quanti

13 des (84 versus 77 mg/dL, P = 0.01) and lower high-density lipoprotein (46 versus 60 mg/dL, P = 0.004)

14 ycerides (-53.7 +/- 116.4 mg/dL, P < 0.001), high-density lipoprotein (8.2 +/- 12.9 mg/dL, P < 0.001)

15 tly associated with higher concentrations of high-density lipoprotein (9%) and sex-hormone binding gl

16 In Abca1 knockout mice (Abca1(ko)), high density lipoproteins and ApoA-I are virtually lacki

17 n under shear stress can be modulated by the high-density lipoprotein and apolipoprotein A-I (HDL/Apo

18 ce, triglycerides, type-2 diabetes mellitus, high-density lipoprotein and low-density lipoprotein cho

19 High-density lipoprotein and triglyceride values rapidly

20 17 coincided with a significant QTL for HDL (high-density lipoprotein) and a suggestive QTL for non-H

21 ts and increase in hsCRP, total cholesterol, high-density lipoprotein, and low-density lipoprotein le

22 n E levels were also measured in serum, LDL, high-density lipoprotein, and red blood cell membranes a

23 ure, triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol were not

24 Total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride levels all si

25 C-reactive protein, low-density lipoprotein, high-density lipoprotein, and triglyceride single-nucleo

26 , low-density lipoprotein (LDL) cholesterol, high-density lipoprotein, and triglycerides], lipoprotei

27 ) low-density lipoprotein oxidizability, (2) high-density lipoprotein antioxidant/anti-inflammatory c

28 tion to previously reported triglyceride and high-density lipoprotein associations, the variant was a

29 xed to glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) on

30 point to understand the molecular details of high density lipoprotein biogenesis.

31 (Apo)A-I, the major lipid-binding protein of high-density lipoprotein, can prevent autoimmunity and s

32 triglycerides, but was associated with lower high density lipoprotein cholesterol (-0.014 standard de

33 We predicted height, high density lipoprotein cholesterol (HDL) and body mass

34 nterestingly, significantly higher levels of high density lipoprotein cholesterol (HDLc) were observe

35 enzymatic activity and a 35% increase of the high density lipoprotein cholesterol that was observed u

36 een duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol >/= 160 mg/dL) in e

37 oprotein cholesterol (LDL-C) <160 mg/dl, and high-density lipoprotein cholesterol >/=40 mg/dl.

38 events and control of 6 RFs (no smoking, non-high-density lipoprotein cholesterol <130 mg/dl, triglyc

39 lesterol (1.6 [1.1-2.1]), and borderline low high-density lipoprotein cholesterol (1.4 [1.0-1.8]) rem

40 lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), ap

41 statistically significantly increased serum high-density lipoprotein cholesterol (13 trials; net cha

42 showed nominal significant association with high-density lipoprotein cholesterol (2 SNPs), low-densi

43 e saw a small increase in rate of change for high-density lipoprotein cholesterol (beta = 0.28 mg/dL;

44 associated in opposite directions with both high-density lipoprotein cholesterol (beta coefficient=-

45 carriers, carriers of PTV at CETP had higher high-density lipoprotein cholesterol (effect size, 22.6

46 s of total cholesterol (TC) (>/= 200 mg/dL), high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL)

47 rs have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipo

48 Although the inverse association between high-density lipoprotein cholesterol (HDL-C) and risk of

49 y artery disease (CAD), but the relevance of high-density lipoprotein cholesterol (HDL-C) and triglyc

50 Low levels of high-density lipoprotein cholesterol (HDL-C) are common

51 The prognostic importance of high-density lipoprotein cholesterol (HDL-C) as a specif

52 LDL-c from 155 to 128 mg/dL (P < .001), and high-density lipoprotein cholesterol (HDL-c) from 50.3 t

53 ational epidemiologic studies, higher plasma high-density lipoprotein cholesterol (HDL-C) has been as

54 cause of ischemic stroke, and a low level of high-density lipoprotein cholesterol (HDL-C) is also con

55 diet only), red wine significantly increased high-density lipoprotein cholesterol (HDL-C) level by 0.

56 ubfamily A, member 1 (ABCA1) and circulating high-density lipoprotein cholesterol (HDL-C) levels in v

57 -density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either

58 Differences in mean high-density lipoprotein cholesterol (HDL-C), LDL-C, and

59 ol levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-densit

60 Levels of serum cholesterol, high-density lipoprotein cholesterol (HDL-C), low-densit

61 a small, and chitosan an impressive rise in high-density lipoprotein cholesterol (HDL-C).

62 variants at the GALNT2 locus associated with high-density lipoprotein cholesterol (HDL-C).

63 NAFLD, such as hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C).

64 vels of TRAP, was positively associated with high-density lipoprotein cholesterol (HDL-C; beta = 8.36

65 ated locus associated with triglycerides and high-density lipoprotein cholesterol (HDL-C; cg27243685;

66 Low levels of high-density lipoprotein cholesterol (HDLc) have been as

67 lesterol (decreased in LFHC group only), and high-density lipoprotein cholesterol (increased in VHFLC

68 cholesterol (LDL-C), triglycerides, and non-high-density lipoprotein cholesterol (non-HDL-C) present

69 t also LDL-related biomarkers, including non-high-density lipoprotein cholesterol (non-HDL-C), apolip

70 nsity lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C).

71 ith >/= 5 births had the highest odds of low high-density lipoprotein cholesterol (OR, 1.5; 95% confi

72 lipoprotein cholesterol, and HbA1c and lower high-density lipoprotein cholesterol (P < 0.001 for all)

73 sedentary time was associated with decreased high-density lipoprotein cholesterol (P=0.04), and incre

74 and years of schooling (rG=0.18, s.e.=0.03), high-density lipoprotein cholesterol (rG=0.28, s.e.=0.05

75 CI, 1.11-1.94]), an elevated serum level of high-density lipoprotein cholesterol (RR per 1-SD increa

76 The total cholesterol to high-density lipoprotein cholesterol (TC/HDL-C) ratio, e

77 notypes: V(G)/V(p)=31.4%, P<3.1x10(-11)) and high-density lipoprotein cholesterol (V(G)/V(p)=26.4%, P

78 low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and trigly

79 asting lipid fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-densit

80 ed for LDL-C were observed with achieved non-high-density lipoprotein cholesterol and apolipoprotein

81 t association was found for higher levels of high-density lipoprotein cholesterol and decreased preva

82 adjusted models, women had higher levels of high-density lipoprotein cholesterol and high-density li

83 cational attainment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivit

84 e MetS components and CA, except for reduced high-density lipoprotein cholesterol and nonfasting gluc

85 oprotein cholesterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides t

86 terol; lipoprotein(a), apolipoprotein B, and high-density lipoprotein cholesterol are largely unaffec

87 for other cardiac risk factors including non-high-density lipoprotein cholesterol at 55 years of age

88 mprove clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%.

89 re, body mass index, apolipoprotein A-1, and high-density lipoprotein cholesterol concentration (beta

90 ted fasting blood glucose concentration, low high-density lipoprotein cholesterol concentration, hype

91 rapy, body mass index, heart rate, total and high-density lipoprotein cholesterol concentrations, smo

92 pectroscopy and a validated ex vivo assay of high-density lipoprotein cholesterol efflux capacity.

93 Neither low- nor high-density lipoprotein cholesterol GRS was significant

94 Total serum and high-density lipoprotein cholesterol have been considere

95 exposure to even moderate elevations in non-high-density lipoprotein cholesterol have elevated risk

96 ansaminase, white blood cell count and lower high-density lipoprotein cholesterol in men, and with hi

97 ), triglyceride level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, an

98 f at least 70 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 1

99 physical activity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blo

100 ely associated with treated hypertension and high-density lipoprotein cholesterol level.

101 ted to physical or mental stress; and higher high-density lipoprotein cholesterol level.

102 ice lacking T39 (T39(-/-)) display increased high-density lipoprotein cholesterol levels associated w

103 iglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34

104 s were also more likely to smoke, have lower high-density lipoprotein cholesterol levels, and have hi

105 rglycemia, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, high blood

106 s in total, low-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in triglyce

107 ompared with controls, despite no changes in high-density lipoprotein cholesterol or other circulatin

108 leukin-10 remained persistently elevated and high-density lipoprotein cholesterol persistently depres

109 h ARIC metabolic phenotypes, including total:high-density lipoprotein cholesterol ratio (rG=-0.44, P=

110 vents, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associat

111 ded risk factors were body mass index, total:high-density lipoprotein cholesterol ratio, and systolic

112 Total and high-density lipoprotein cholesterol similarly increased

113 gene, TEAD2, is found to be associated with high-density lipoprotein cholesterol through gene-based

114 than in WT mice (2.6 versus 0.4 mmol/L), and high-density lipoprotein cholesterol was significantly l

115 High levels of high-density lipoprotein cholesterol were associated wit

116 lipoprotein cholesterol and triglycerides to high-density lipoprotein cholesterol were calculated.

117 of higher systolic blood pressure and lower high-density lipoprotein cholesterol with Carotid artery

118 nce, blood pressure, triglycerides, glucose, high-density lipoprotein cholesterol) at 15 (n=512), 16

119 7 (low-density lipoprotein cholesterol), 8 (high-density lipoprotein cholesterol), 14 (triglycerides

120 epatitis A), biochemical (e.g., carotenoids, high-density lipoprotein cholesterol), physiological (e.

121 largely explained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than incre

122 ait (for example, rs7115089, miR-125b-5p and high-density lipoprotein cholesterol).

123 rol, 109.23 mg/dL (103.68-114.79 mg/dL); for high-density lipoprotein cholesterol, 42.80 mg/dL (39.84

124 erol, 71 single-nucleotide polymorphisms for high-density lipoprotein cholesterol, and 40 single-nucl

125 olesterol, the ratio of total cholesterol to high-density lipoprotein cholesterol, and 8-OHdG levels.

126 e relationship between additional LDL-C, non-high-density lipoprotein cholesterol, and apolipoprotein

127 r age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass inde

128 c biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive pro

129 diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and glucose levels

130 lic abnormalities (high fasting glucose, low high-density lipoprotein cholesterol, and high triglycer

131 Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of tota

132 ia, neuroticism, educational attainment, and high-density lipoprotein cholesterol, and significant ne

133 Total cholesterol, high-density lipoprotein cholesterol, and triglycerides

134 Lipid traits (total, low-density and high-density lipoprotein cholesterol, and triglycerides)

135 were also observed in total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B,

136 ding hypertension, hypertriglyceridemia, low high-density lipoprotein cholesterol, central obesity, a

137 -regression for various covariates including high-density lipoprotein cholesterol, each 1 unit of nat

138 ssure, ratio of fasting total cholesterol to high-density lipoprotein cholesterol, estimated glomerul

139 abolic biomarkers (diastolic blood pressure, high-density lipoprotein cholesterol, fasting and 2-hour

140 dominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol, high blood pressur

141 ent for low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, lipoprotein(a), tr

142 High-density lipoprotein cholesterol, low-density lipopr

143 ture mapping analysis for total cholesterol, high-density lipoprotein cholesterol, low-density lipopr

144 e-mapping analysis that were associated with high-density lipoprotein cholesterol, low-density lipopr

145 -wide DNA methylation and blood lipid levels high-density lipoprotein cholesterol, low-density lipopr

146 rs, carriers of PTV at CETP displayed higher high-density lipoprotein cholesterol, lower low-density

147 ences were found for fasting plasma glucose, high-density lipoprotein cholesterol, or triglycerides w

148 s such as waist circumference, triglyceride, high-density lipoprotein cholesterol, systolic and diast

149 and fasting blood sample (total cholesterol, high-density lipoprotein cholesterol, triglycerides, glu

150 actors: low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, typ

151 rable objective biomarkers (concentration of high-density lipoprotein cholesterol, vitamin D and C-re

152 cholesterol and triglyceride, and increasing high-density lipoprotein cholesterol.

153 effect estimate as large as that of total or high-density lipoprotein cholesterol.

154 s of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol.

155 density lipoprotein cholesterol families) or high-density lipoprotein cholesterol.

156 n part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol.

157 may preferentially improve triglycerides and high-density lipoprotein cholesterol.

158 tolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol.

159 h diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol.

160 ity lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser e

161 or remnant cholesterol, and -8 mg/dl for non-high-density lipoprotein cholesterol; lipoprotein(a), ap

162 s of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of hi

163 ntly associated with total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-C), low-densit

164 d alcohol and was positively associated with high-density-lipoprotein cholesterol and intakes of poly

165 lin resistance), serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio TG/HDL-C, or

166 sterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, or triglyceride, 4

167 ypes of MDD with changes of fasting glucose, high-density lipoprotein-cholesterol, triglycerides, sys

168 tion between CCR2 and CX3CR1 expressions and high-density lipoprotein-cholesterol, whereas CCR5 expre

169 ted QT interval, HR-corrected QT interval or high-density lipoprotein-cholesterol.

170 lesterol, 2) low-density lipoprotein, and 3) high-density lipoprotein compared to group C.

171 ciated with very low-density lipoprotein and high-density lipoprotein composition measures, other cho

172 .30 and 0.14, respectively; both p < 0.001), high-density lipoprotein (correlation coefficient 0.16 a

173 We validate our method using a real mouse high-density lipoprotein data (HDL) and show that CAVIAR

174 (-/-)) show decreased fatty liver, increased high-density lipoprotein, decreased low-density lipoprot

175 es mellitus, serum potassium, serum albumin, high-density lipoprotein, estimated glomerular filtratio

176 )particles to indicate their relationship to high-density lipoproteins formed by human apolipoprotein

177 Cholesterol efflux capacity of high-density lipoproteins from J774 macrophages after cA

178 omain protein 39B (Ttc39b, C9orf52) (T39), a high-density lipoprotein gene discovered in human genome

179 resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant shared gene eff

180 resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had significant shared gene eff

181 Structural and functional aspects of high-density lipoproteins have been studied for over hal

182 ed from the circulation and transferred from high density lipoprotein (HDL) - a main carrier of chole

183 ups and assessed for total cholesterol (TC), high density lipoprotein (HDL) and low density lipoprote

184 body fat -0.00516 (95% CI -0.00761--0.0027), high density lipoprotein (HDL) cholesterol 0.00179 (95%

185 ipid transfer protein (PLTP) participates in high density lipoprotein (HDL) metabolism.

186 Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)-associated protein with a

187 all to the liver) is terminated by selective high density lipoprotein (HDL)-cholesteryl ester (CE) up

188 SR-BI is the main receptor for high density lipoproteins (HDL) and mediates the bidirec

189 s designed for the analysis of lipoproteins, high density lipoproteins (HDL), apoproteins, and lipid

190 and function of the potent anti-inflammatory high-density lipoprotein (HDL) and accelerated atheroscl

191 A1 (apoA1) is the major protein component of high-density lipoprotein (HDL) and has well documented a

192 We identified that component as high-density lipoprotein (HDL) and its major apolipoprot

193 1, is a lipoprotein receptor that binds both high-density lipoprotein (HDL) and low-density lipoprote

194 Associations were independent of high-density lipoprotein (HDL) and non-HDL cholesterol,

195 Insulin resistance and low high-density lipoprotein (HDL) are associated with pulmo

196 ng of apolipoprotein A-I (apoA1) and nascent high-density lipoprotein (HDL) assembly is not well unde

197 6, 0.154; P = 0.007) and the ratio of TGs to high-density lipoprotein (HDL) cholesterol (beta = 2.689

198 eceptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C).

199 = 16.4 mg/dL, 95% CI: 11.2, 21.5), and lower high-density lipoprotein (HDL) cholesterol (MD = -2.1 mg

200 tein B were higher after VA than after iTFA; high-density lipoprotein (HDL) cholesterol and apolipopr

201 Serum levels of high-density lipoprotein (HDL) cholesterol and apolipopr

202 observing associations between low levels of high-density lipoprotein (HDL) cholesterol and cardiovas

203 The causal role of high-density lipoprotein (HDL) cholesterol in cardioprot

204 l attainment, openness to new experience and high-density lipoprotein (HDL) cholesterol levels are mo

205 Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to red

206 reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels.

207 known to have effects on serum levels of non-high-density lipoprotein (HDL) cholesterol that alter th

208 iglycerides were 13% lower and the levels of high-density lipoprotein (HDL) cholesterol were 7% highe

209 rease in total, low-density lipoprotein, and high-density lipoprotein (HDL) cholesterol, but not in t

210 d body mass index (BMI), C-reactive protein, high-density lipoprotein (HDL) cholesterol, forced expir

211 e cardiometabolic risk-factor profile [lower high-density lipoprotein (HDL) cholesterol, higher total

212 ed circulating lipid profiles, in particular high-density lipoprotein (HDL) cholesterol, in overweigh

213 fasting glucose, insulin, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density

214 ns of abnormal values for total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density

215 f low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycer

216 the median (n = 83) was older and had lower high-density lipoprotein (HDL) cholesterol, phospholipid

217 s such as waist circumference, triglyceride, high-density lipoprotein (HDL) cholesterol, systolic and

218 , low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triacylglyce

219 mass index (BMI), waist circumference (WC), high-density lipoprotein (HDL) cholesterol, triglyceride

220 as well as low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

221 ], and a positive association was shown with high-density lipoprotein (HDL) cholesterol.

222 ents whether obesity-induced endothelial and high-density lipoprotein (HDL) dysfunction is rapidly im

223 erse cholesterol transport (RCT) and reduces high-density lipoprotein (HDL) function in vivo.

224 nder LPS challenge, leading to modulation of high-density lipoprotein (HDL) in animals.

225 High-density lipoprotein (HDL) is a heterogeneous popula

226 There is though a hypothesis that low high-density lipoprotein (HDL) levels in this group of p

227 rotein A-I (apoA-I) plays a critical role in high-density lipoprotein (HDL) maturation.

228 othesis that cholesterol efflux capacity and high-density lipoprotein (HDL) particle concentration pr

229 P is bound to apolipoprotein M (ApoM) in the high-density lipoprotein (HDL) particle, the immunologic

230 High-density lipoprotein (HDL) particles are involved in

231 DL, very low-density lipoprotein (VLDL), and high-density lipoprotein (HDL) particles.

232 mational reorganization during remodeling of high-density lipoprotein (HDL) particles.

233 low very-low-density lipoprotein (VLDL)/high high-density lipoprotein (HDL) profile.

234 that functions as a physiologically relevant high-density lipoprotein (HDL) receptor whose primary ro

235 Twenty-four hours post-MI measurements of high-density lipoprotein (HDL) triglycerides (HDL-TG) pr

236 line (PBS) without significant interference: high-density lipoprotein (HDL) yields 4-6% of the LDL si

237 ified AH is 4%-23% in eQTLs, 35% in GWASs of high-density lipoprotein (HDL), and 23% in GWASs of schi

238 rides, and strong negative associations with high-density lipoprotein (HDL), HDL-diameter, HDL-C, HDL

239 ared with the SSGWAS for blood lipid traits (high-density lipoprotein (HDL), low-density lipoprotein

240 Lipoproteins, such as high-density lipoprotein (HDL), low-density lipoprotein

241 The CHEESE diet caused a 5% higher high-density lipoprotein (HDL)-cholesterol concentration

242 r HCV entry) and also blocks SR-BI-dependent high-density lipoprotein (HDL)-mediated enhancement of v

243 LPS binding protein, competitively inhibits high-density lipoprotein (HDL)-mediated LPS association

244 , is known to cause a dramatic rise in small high-density lipoprotein (HDL).

245 ]sitostanol- and [(14) C]cholesterol-labeled high-density lipoprotein (HDL).

246 particularly when present on the surface of high-density lipoprotein (HDL).

247 to cholesterol, promoting the maturation of high-density lipoproteins (HDL) from discoidal to spheri

248 etabolism and anti-atherogenic properties of high-density lipoproteins (HDL) is unknown.

249 Beneficial effects of high-density lipoproteins (HDL) seem altered in patients

250 gosine-1-phosphate (S1P) is a constituent of high-density lipoproteins (HDL) that contributes to thei

251 holesterol esters (CE) from atheroprotective high-density lipoproteins (HDL) to atherogenic low-densi

252 Early forms of high-density lipoproteins (HDL), nascent HDL, are formed

253 id rafts, is a receptor for cholesterol-rich high-density lipoproteins (HDL).

254 justed follow-up blood lipid concentrations (high-density lipoprotein [HDL] and low-density lipoprote

255 cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], and triglycerides [TGs])

256 eins including brain (apoE) and circulating (high-density lipoprotein, HDL) synergize to facilitate A

257 The biological functions of high-density lipoproteins (HDLs) contribute to explainin

258 We recently showed that high-density lipoproteins (HDLs) enhance ischemia-mediat

259 h a genetic variant previously correlated to high-density lipoprotein in a human genome-wide associat

260 nsity lipoprotein is causal for CHD, whereas high-density lipoprotein is not.

261 lectrochemical responses of purified low and high density lipoproteins (LDL and HDL, respectively) we

262 predicting height, body mass index (BMI) and high-density lipoprotein level (HDL) in two data cohorts

263 ounder population sequences: chr16:70790626 (high-density lipoprotein levels beta -1.71 (SE 0.25), P=

264 Increasing high-density lipoprotein levels in Apoa1bp(-/-) mice by

265 either prevalent CVD or CVD risk factors and high-density lipoprotein levels less than 50 mg/dL (<55

266 glyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coro

267 ating adiponectin was associated with higher high-density lipoprotein lipids and lower very-low-densi

268 trong inverse associations were observed for high-density lipoprotein measures, e.g., high-density li

269 tein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux cap

270 Here we demonstrate that high-density lipoprotein-mimicking nanodiscs coupled wit

271 e, 2-h glucose and insulin, haemoglobin A1c, high-density lipoprotein or blood pressure.

272 oriasis (OR, 3.90; 95% CI, 1.57-9.66); lower high-density lipoprotein (OR, 0.99; 95% CI, 0.98-0.99);

273 of high-density lipoprotein cholesterol and high-density lipoprotein particle concentration, leptin,

274 logical samples, with a special focus on non-high-density-lipoprotein particle concentrations (non-HD

275 TLF-1 is a subclass of high density lipoprotein particles defined by two primat

276 s (72.4 vs. 64.6; P = 0.02), decreased large high-density lipoprotein particles (5.3 vs. 6.7; P < 0.0

277 ipid transfer protein, and incorporated into high-density lipoprotein particles.

278 hway as well as the extracellular matrix and high-density lipoprotein pathways in the aetiology of AM

279 Despite the lower high-density lipoprotein plasma levels, both transgenic

280 ved as danger signals; efflux cholesterol to high-density lipoprotein; proliferate and migrate; under

281 g/dL; 95% CI: 0.9, 9.7 mg/dL) and the LDL to high-density lipoprotein ratio (5 trials; net change: 0.

282 tatus; alcohol intake; SBP; DBP; cholesterol:high-density lipoprotein ratio; diabetes; body mass inde

283 er receptors BI (SR-BI) and BII (SR-BII) are high-density lipoprotein receptors that recognize variou

284 ApoA-I, the major protein of plasma high-density lipoprotein, removes cellular cholesterol a

285 otein cholesterol ratio (rG=-0.44, P=0.005), high-density lipoprotein (rG=-0.48, P=0.005), systolic b

286 we describe the development of reconstituted high-density lipoprotein (rHDL)-facilitated TAM PET imag

287 ree clinically relevant nanomedicines, i.e., high-density lipoprotein ([S]-HDL), polymeric micelles (

288 eptide nanoparticles that mimic native human high density lipoproteins significantly increases peptid

289 for high-density lipoprotein measures, e.g., high-density lipoprotein size (OR = 0.36, 0.30-0.42) and

290 tal (standardized estimate, 0.06; P = .050), high-density lipoprotein (standardized estimate, 0.07; P

291 ipoprotein subclasses, with the exception of high-density lipoprotein subclasses, which displayed a m

292 Fenugreek also significantly improved high-density lipoprotein to low-density lipoprotein rati

293 density lipoprotein/low-density lipoprotein, high-density lipoprotein, triglycerides, cytokines or bi

294 D and at least 1 of low-density lipoprotein, high-density lipoprotein, triglycerides, type 2 diabetes

295 ir association with low-density lipoprotein, high-density lipoprotein, triglycerides, type 2 diabetes

296 ng the gut microbiome explained </= 25.9% of high-density lipoprotein variance, significantly outperf

297 her (95% confidence interval, 1.71-2.97) and high-density lipoprotein was 1.62 mg/dL lower (95% confi

298 micelles, and nanocrystal-core reconstituted high-density lipoproteins, we have shown the approach's

299 terol (TC), TG, low-density lipoprotein, and high-density lipoprotein were measured.

300 rary's nanoparticles are based on endogenous high-density lipoprotein, which can preferentially deliv